In 2014 North America led the Anti-Bacterial Drugs Market with a share of 38.9%

The Anti-Bacterial segment includes few of the oldest classes of drugs that have enriched the industry over past several decades. With over 80% of the total market share being held by generics, the major brands hold a small percentage of shares in the market. In 2014, the global anti-bacterial drugs market was valued at US$ 43,444.9 million and is anticipated to grow to US$ 49,871.0 million by 2019 at a CAGR of 3.1%. Over the past two decades, there has been a significant rise of drug resistance among humans. MRSA and other drug resistant superbugs and microbes have always been a challenge for the pharmaceutical companies. In the face of rising incidence of hospital and community acquired bacterial diseases, the market for antibacterials as a whole is expected to benefit. As compared to the last decade, companies such as Cubist and Cempra are leading the way in introducing anti-bacterials posed to combat the challenges of drug resistant super bugs. At least 39 anti-bacterial compounds are undergoing clinical trials across a variety of classes, with 25 of these in phase 2 or 3 clinical trials, and 3 compounds under review at the FDA. There had been no new classes of anti-bacterial drugs for almost thirty years, however a latest article researchers have discovered a new drug, called teixobactin, which marks the launch of a new class of antibiotics.

Market Drivers:

  • Increasing incidence of hospital and community acquired bacterial infections pushing growth of brands and generics Improving
  • Legal Framework for provision of Incentives expected to drive growth

Market Inhibitors:

  • Limited pipeline drugs and absence of new indication targets may lead to significant erosion against generics

Free Sample Report@–Forecast-2015-2019/sample2

Current Drugs Covered In This Report:

  • Cubicin
  • Teflaro/Zinforo
  • Dificid
  • Dalvance
  • Orbactiv
  • Sivextro
  • Zerbaxa
  • Avycaz
  • Zyvox
  • Avelox
  • Augmentin
  • Zosyn/Tazocin
  • Invanz
  • Tygacil

Pipeline Drugs Covered In This Report:

  • Surotomycin
  • Solithromycin
  • Delafloxacin
  • Plazomycin
  • Taksta
  • Cadazolid
  • Carbavance
  • Eravacycline

Click For Full Report@–Forecast-2015-2019/2

Key Players Covered In This Report:

  • Actavis Pharmaceuticals
  • Astrazeneca
  • Cempra Pharmaceuticals
  • Cubist Pharmaceuticals
  • Durata Therapeutics
  • Forest Laboratories
  • GlaxoSmithKline (GSK)

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s